Major Depressive Disorder Clinical Trial
Official title:
Genetic Predictors of Response to a Computerized Self-help Program for Depression
Verified date | November 2015 |
Source | University of Texas at Austin |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The goal of this project is to determine whether genetic information can be used to predict response to an internet-based treatment of depression. Several studies now indicate that completing an internet-based treatment for depression, called Deprexis, can significantly improve symptoms of depression. However, not everyone improves. The purpose of this study is to determine whether genetic profile can predict who is likely to improve.
Status | Completed |
Enrollment | 500 |
Est. completion date | November 2015 |
Est. primary completion date | November 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - English-speaking - Have reliable access to the internet (i.e., dialup or broadband access) - Be willing to donate saliva for DNA research - Have a current symptoms of depression - Be stable on medication and/or therapy (i.e. no changes within 2 weeks of study entry) Exclusion Criteria: - Any diagnosis of a psychotic or bipolar disorder - Meeting for alcohol/drug dependence in the past year - Having current suicidal risk warranting crisis intervention |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | The University of Texas at Austin | Austin | Texas |
Lead Sponsor | Collaborator |
---|---|
University of Texas at Austin | Brown University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quick Inventory of Depressive Symptomatology (Self-Report) (QIDS-SR-16) | Administred every 2 weeks while the participant is engaged in the online deprexis treatment program to measure depression symptom severity. | No | |
Secondary | Hamilton Depression Rating Scale (HAM-D) | The HAM-D will be completed during the pre- and post-treatment phone interviews to assess depression symptom severity. | No | |
Secondary | Inventory of Depression and Anxiety Symptoms (IDAS) | The IDAS will be completed as part of the pre- and post-treatment questionnaires to assess for symptoms of depression and anxiety. | No | |
Secondary | Psychiatric Diagnostic Screening Questionnaire (PDSQ) | The PDSQ will be completed as part of the pre- and post-treatment questionnaires to screen for the most common DSM-IV Axis I disorders.. | No | |
Secondary | Risky Families Questionnaire (RFQ) | The RFQ will be completed as part of the pre-treatment questionnaires to assess early familial experiences and the harshness of family climate. | No | |
Secondary | Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ) | The ATRQ will be administered as part of the pre-treatment questionnaires to evaluate psychotropic efficacy. | No | |
Secondary | Sheehan Disability Scale (SDS) | The SDS will be completed as part of the pre- and post-treatment questionnaires to evaluate symptom-related disability. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |